DUBLIN, Ireland, July 8, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Dignity Sciences Limited, a privately held biopharmaceutical company, today announced positive Phase II results for DS107E (DGLA cream), as a topical treatment for atopic dermatitis.
This study was a randomized, placebo-controlled, double-blind, multi-centre Phase II study to investigate the efficacy and safety of topically applied DS107E (DGLA cream) and the dose-response of three doses (0.1%, 1%, 5%) of DS107E and placebo in patients who have mild or moderate atopic dermatitis.
Help employers find you! Check out all the jobs and post your resume.
